New hope for rare gut tumors? phase 2 trial launches
NCT ID NCT07640737
First seen Jun 11, 2026 · Last updated Jun 20, 2026 · Updated 2 times
Summary
This phase 2 trial tests a new drug called AUR103 calcium in 30 people with advanced neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug twice daily until their disease progresses or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE (NE) TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hoag Family Cancer Institute
Newport Beach, California, 92657, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic Cancer Center (MCCC)
Phoenix, Arizona, 85054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic Cancer Center (MCCC)
Rochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic Hospital - Florida
Jacksonville, Florida, 32224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AUR103 calcium
What this could lead to
If successful, this could point toward a new treatment option for people with advanced neuroendocrine tumors that have stopped responding to other therapies.
What could go wrong
This is an early phase 2 proof-of-concept study with only 30 participants. It may not show enough benefit to move forward, and side effects are still being evaluated.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.